Preprint Article Version 1 This version is not peer-reviewed

Predicting Survival of Metastatic Clear Cell Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitor Based Sequential Therapy

Javier C. Angulo
* ,
Gorka Larrinaga
* ,
David Lecumberri
,
Ane Miren Iturregui
,
Jon Danel Solano-Iturri
,
Charles H. Lawrie
,
María Armesto
,
Juan F. Dorado
,
Caroline E. Nunes-Xavier
,
Rafael Pulido
,
Claudia Manini
,
José I. López
Version 1 : Received: 25 July 2024 / Approved: 26 July 2024 / Online: 26 July 2024 (06:23:32 CEST)

How to cite: Angulo, J. C.; Larrinaga, G.; Lecumberri, D.; Iturregui, A. M.; Solano-Iturri, J. D.; Lawrie, C. H.; Armesto, M.; Dorado, J. F.; Nunes-Xavier, C. E.; Pulido, R.; Manini, C.; López, J. I. Predicting Survival of Metastatic Clear Cell Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitor Based Sequential Therapy. Preprints 2024, 2024072128. https://doi.org/10.20944/preprints202407.2128.v1 Angulo, J. C.; Larrinaga, G.; Lecumberri, D.; Iturregui, A. M.; Solano-Iturri, J. D.; Lawrie, C. H.; Armesto, M.; Dorado, J. F.; Nunes-Xavier, C. E.; Pulido, R.; Manini, C.; López, J. I. Predicting Survival of Metastatic Clear Cell Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitor Based Sequential Therapy. Preprints 2024, 2024072128. https://doi.org/10.20944/preprints202407.2128.v1

Abstract

(1) Objective: To develop a clinically useful nomogram that may provide a more individualized and accurate estimation of cancer-specific survival (CSS) for patients with clear-cell (CC) metastatic renal cell carcinoma (mRCC) treated with nephrectomy and tyrosine kinase Inhibitor (TKI) based sequential therapy; (2) Methods: A prospectively maintained database of 145 patients with mRCC treated between 2008-2018 was analyzed to predict CSS of patients receiving sunitinib and 2nd and 3rd line therapies according to current standards of practice. A nomogram taking into account four independent clinical predictors (ECOG status, IMDC score, MASS and RECIST response criteria) was calculated. The corresponding 1- to 10-year CSS probabilities were then determined from the nomogram; (3) Results: The median age was 60 years (95% CI 57.9-61.4). Disease was metastatic at diagnosis in 59 (40.7%) and 86 (59.3%) developed metachronous metastasis after nephrectomy. Patients were followed for a median 48 (IQR 72; 95% CI 56-75.7) months after first-line TKI initiation. Concordance probability estimator for the nomogram is 0.778 ± 0.02 (mean ± SE); (4) Conclusions: A nomogram to predict CSS in patients with CC mRCC that incorporates patient status, clinical risk classification and response criteria to first-line TKI at 3 months is presented. This new tool may be useful to clinicians assessing risk and prognosis of patients with mRCC.

Keywords

metastatic renal cell carcinoma; tyrosine kinase inhibitor sunitinib; nomogram; cancer-specific survival; prognosis; treatment response

Subject

Medicine and Pharmacology, Urology and Nephrology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.